Implantica AG's Annual General Meeting Highlights and Resolutions from June 2026

Highlights from the Implantica AG Annual General Meeting

On June 10, 2026, Implantica AG held its annual general meeting (AGM) in Ruggell, Liechtenstein. This meeting was pivotal for the company's shareholders as it outlined key resolutions and frameworks for the forthcoming fiscal period.

Among the core activities at the AGM was the approval of the 2025 annual report, which included both statutory and consolidated financial statements. The shareholders recognized the auditors' reports, showcasing confidence in the company's financial practices for the year.

Financial Resolutions and Dividend Decisions

A significant decision made during the AGM was the resolution to carry forward the net loss incurred in the 2025 financial year. This decision aligns with Implantica AG's financial strategy, which also involved the board's resolution not to distribute any dividends for the year. This can suggest a focus on reinvestment over distributing immediate profits to shareholders.

Board Discharge and Remuneration Approvals

Furthermore, the meeting resolved to exonerate the board of directors, executive management, and auditors from liability for their performances in the past financial year. This indicates approval of their management and operational strategies during a challenging year.

The AGM also confirmed the total remuneration package for the board and executive management, amounting to TEUR 192 and TEUR 2,016 respectively. The outlined remuneration package emphasized fixed compensation, along with social security and pension contributions, reflecting a comprehensive approach to staff incentives through long-term share-based plans as stipulated by IFRS standards.

Re-elections of Board Members

In line with continuity in governance, shareholders re-elected board members Liselott Kilaas, Johan Bojs, Tomas Puusepp, and Stephan Siegenthaler for terms lasting until the next AGM. Liselott Kilaas retained the position of chairman, and Johan Bojs continued as vice-chairman, underscoring stability in the company's leadership.

The meeting also saw the re-election of Johan Bojs and Tomas Puusepp for the nomination and remuneration committee, ensuring that key governance roles are held by experienced members familiar with the company’s operations.

Auditor Re-elections

The attendees acknowledged the re-election of KPMG (Liechtenstein) AG as the company’s auditor for the 2026 fiscal year, which is indicative of the shareholders' trust in KPMG’s capability to oversee Implantica's financial auditing processes effectively.

Future Prospects

The proceedings of the AGM, encapsulated in the meeting minutes, will be accessible on the company’s website, further promoting transparency among shareholders. Progressively, Implantica AG continues to innovate in medical technology, notably with its flagship product, RefluxStop®, which targets gastroesophageal reflux disease (GERD). This device aims to offer transformative effects within anti-reflux surgery, backed by promising clinical outcomes.

Implantica AG aims to integrate advanced technologies in implantable solutions, including eHealth platforms for remote monitoring and wireless charging technologies. Such innovations promise to reduce medical costs and enhance patient experiences. The company's stock is traded on Nasdaq First North Premier Growth Market under ticker IMP A SDB, marking its significant presence in the medical technology sector.

In conclusion, the recent AGM not only reinforced the company’s standing from a financial perspective but also solidified strategic choices that place Implantica AG on a promising trajectory for innovation and growth in the medical device landscape.

For additional details, shareholders can access comprehensive information on the company's advancements and operational updates via the Implantica official website: www.implantica.com.